|
[Related PubMed/MEDLINE]
Total Number of Papers: 110
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
A systematic review evaluating the efficacy and factor consumption of long-acting recombinant factor VIII products for the prophylactic treatment of hemophilia A. |
ABR, rFVIII |
| 2 |
2020 |
Cabotegravir and rilpivirine for the treatment of HIV. |
ART, CR, PLWH |
| 3 |
2020 |
Evaluation of a Long-Acting Opioid Restriction Policy: Does Restriction Reduce the Need for Naloxone Reversal? |
CI, OR |
| 4 |
2020 |
Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir. |
PK, UGT |
| 5 |
2020 |
Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy. |
ART, WIHS |
| 6 |
2020 |
Exploration into the opinions of patients with HIV, healthcare professionals and the lay public of the use of microneedles in clinical practice: highlighting the translational potential for their role in HIV infection. |
ART, HCPs, LP, MN |
| 7 |
2020 |
Identifying appropriate candidates for long-acting antiretroviral therapy: findings from a survey of health care providers in the ATLAS-2M trial. |
ART, CAB, HCPs, RPV |
| 8 |
2020 |
Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. |
IM |
| 9 |
2020 |
Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling. |
NRTI, PBMCs, PBPK, PrEP, s.c, TAF, TFV, TFV-DP |
| 10 |
2020 |
Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues. |
ARVs, LA-ICP-MS, PK, RPV |
| 11 |
2020 |
Synthesis and Characterization of Long-Acting Darunavir Prodrugs. |
ART, DRV |
| 12 |
2020 |
Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications. |
PrEP, TAF, TAFfb, UA |
| 13 |
2020 |
Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant. |
ART, NHP, PBMC, SHIV, TAF, TFV-DP |
| 14 |
2019 |
2-Hydroxypropyl-beta-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis. |
ARV, CAB, HIV, INSTI, PK, PrEP |
| 15 |
2019 |
A long acting nanoformulated lamivudine ProTide. |
MDM, NM23TC, PK |
| 16 |
2019 |
A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. |
AEs, PD, PK, PrEP, RPV |
| 17 |
2019 |
A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on 68Ga-DOTATATE Uptake in Patients with Neuroendocrine Tumors. |
NETs, SSAs |
| 18 |
2019 |
Assessment of the long-acting ivermectin formulation in sheep: Further insight into potential pharmacokinetic interactions. |
ABM, IVM |
| 19 |
2019 |
Characteristics and contraceptive outcomes of women seeking medical or surgical abortion in reproductive health clinics in Cambodia. |
MOTIF |
| 20 |
2019 |
Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP). |
ARV, PCL, PrEP, TAF |
| 21 |
2019 |
Creation of a long-acting rilpivirine prodrug nanoformulation. |
--- |
| 22 |
2019 |
Design, Formulation, and Evaluation of Novel Dissolving Microarray Patches Containing Rilpivirine for Intravaginal Delivery. |
ARV, HIV, IM, MAPs |
| 23 |
2019 |
Healthcare provider perspectives on diagnosing and treating adults with attention-deficit/hyperactivity disorder. |
ADHD, HCP, NPs, PCPs, SA |
| 24 |
2019 |
Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies. |
ADFs, ER |
| 25 |
2019 |
Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission. |
ARV, Hu, NPs, PrEP, PT, T/F, TAF |
| 26 |
2019 |
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study. |
ART, HIVMQ |
| 27 |
2019 |
Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. |
DDIs, PBPK |
| 28 |
2019 |
Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. |
ARV, HIV, IVIVE, NRTI, SSPNs |
| 29 |
2019 |
Synthesis of a long acting nanoformulated emtricitabine ProTide. |
ART |
| 30 |
2019 |
The Patient Perspective: Unmet Treatment Needs in Adults With Attention-Deficit/Hyperactivity Disorder. |
ADHD, AU, SA |
| 31 |
2019 |
Two years in growth hormone 2017-18. |
rhGH |
| 32 |
2018 |
Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension. |
ARV, HIV, IM, MAPs, RPV |
| 33 |
2018 |
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. |
ART, PLHIV |
| 34 |
2018 |
Impact of opioid dose reduction on individuals with chronic pain: results of an online survey. |
CDC, ER, IR |
| 35 |
2018 |
Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States. |
ADHD, DACON, SA |
| 36 |
2018 |
Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals. |
ART, FA |
| 37 |
2018 |
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. |
PrEP |
| 38 |
2018 |
Treatment patterns among adults with ADHD receiving long-acting therapy. |
ADHD, CT, PDC, TTD |
| 39 |
2018 |
Ultra-long-acting removable drug delivery system for HIV treatment and prevention. |
ARVs, NHP |
| 40 |
2017 |
A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. |
ART, BM, CAB, RVP |
| 41 |
2017 |
Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy. |
ER, IR |
| 42 |
2017 |
Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. |
HPLC, MRT, PK/PD |
| 43 |
2017 |
Investigational HIV integrase inhibitors in phase I and phase II clinical trials. |
BIC, CAB, INSTIs, NCINI |
| 44 |
2017 |
Long acting systemic HIV pre-exposure prophylaxis: an examination of the field. |
--- |
| 45 |
2017 |
Pharmacokinetics of Conventional and Long-Acting Oxytetracycline Preparations in Kilis Goat. |
BW, Group I, IM, OTC |
| 46 |
2017 |
Relationship between ivermectin concentrations at the injection site, muscle and fat of steers treated with traditional and long-acting preparations. |
IVM |
| 47 |
2017 |
Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant. |
IGF-I, PEGV, SSAs, SSTRs |
| 48 |
2017 |
The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. |
FN, G-CSF |
| 49 |
2016 |
Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. |
UGT |
| 50 |
2016 |
Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy. |
--- |
| 51 |
2016 |
Time-to-Cessation of Postoperative Opioids: A Population-Level Analysis of the Veterans Affairs Health Care System. |
SA, VHA |
| 52 |
2015 |
Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013. |
ER, MMEs, PBSS, PDMPs |
| 53 |
2015 |
Effectiveness and safety of a long-acting, once-daily, two-phase release formulation of methylphenidate (Ritalin LA) in school children under daily practice conditions. |
CGI, Ritalin LA |
| 54 |
2015 |
Health-care costs and utilization related to long- or short-acting antiepileptic monotherapy use. |
AED, MPRs, SA |
| 55 |
2015 |
Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. |
PBPK |
| 56 |
2015 |
Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers. |
IM, RPV |
| 57 |
2014 |
GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. |
IM |
| 58 |
2014 |
Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. |
GSK744, PrEP |
| 59 |
2014 |
Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. |
IM, RPV |
| 60 |
2014 |
Use of prescription opioids with abuse-deterrent technology to address opioid abuse. |
ER, ER oxycodone, ER oxymorphone |
| 61 |
2013 |
A pilot study to investigate adherence to long-acting opioids among patients with advanced lung cancer. |
PHQ-2, SD |
| 62 |
2013 |
Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies. |
ER, REMS |
| 63 |
2013 |
Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application. |
PIs |
| 64 |
2013 |
Pharmacokinetics of a peroral single dose of two long-acting formulations and an aqueous formulation of doxycycline hyclate in horses. |
AUC, Dox, Dox-beta, Dox-h, MIC, PK/PD, tmax |
| 65 |
2012 |
Evaluation of an experimental urodynamic platform to identify treatment effects: a randomized, placebo-controlled, crossover study in patients with overactive bladder. |
ITT, MCC, OAB, PD1, PD7, PP, UDS |
| 66 |
2012 |
Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids. |
ER, FDA, FDAAA, REMS |
| 67 |
2012 |
Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1. |
ART, NOG |
| 68 |
2012 |
Natural history of opioid dosage escalation post-injury: a cohort study of injured workers in the State of Louisiana. |
SA |
| 69 |
2012 |
Persistent efficacy of a long acting injectable formulation of moxidectin against natural infestations of the sheep nasal bot (Oestrus ovis) in Spain. |
--- |
| 70 |
2012 |
Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. |
--- |
| 71 |
2012 |
Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice. |
ER, FDA, REMS |
| 72 |
2012 |
Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective. |
ADHD, RAMQ, SA |
| 73 |
2012 |
Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program. |
ADHD, DPR, SA, SA-A, SA-M |
| 74 |
2011 |
Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population. |
ADHD, CI, HR, MPH |
| 75 |
2010 |
Evaluation of the persistent activity of moxidectin (10%) long-acting (LA) injectable formulation against Dictyocaulus viviparus, Haemonchus placei, Trichostrongylus axei and Oesophagostomum radiatum infections in cattle. |
--- |
| 76 |
2010 |
Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. |
ATG, GH, IGF, LAR |
| 77 |
2010 |
Therapeutic and persistent efficacy of a long-acting (LA) formulation of ivermectin against Rhipicephalus (Boophilus) microplus (Acari: Ixodidae) and sera concentration through time in treated cattle. |
--- |
| 78 |
2010 |
Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands. |
ADHD, IR |
| 79 |
2009 |
Changes in the use of analogue insulins in 37 206 children and adolescents with type 1 diabetes in 275 German and Austrian centers during the last twelve years. |
SA |
| 80 |
2008 |
Lanreotide Autogel: a review of its use in the management of acromegaly. |
ATG, GH, IGF-I |
| 81 |
2008 |
Spotlight on lanreotide Autogel in acromegaly. |
ATG, GH, IGF-I |
| 82 |
2007 |
Changes and challenges: managing ADHD in a fast-paced world. |
ADHD, CMAP |
| 83 |
2007 |
Predictors of long-acting opioid use and oral versus transdermal route among older Medicaid beneficiaries. |
aOR, SA, TDF |
| 84 |
2006 |
A comparative efficacy of oral prednisone with intramuscular triamcinolone in acute exacerbation of asthma. |
FEV1, FVC |
| 85 |
2005 |
Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients. |
--- |
| 86 |
2005 |
Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. |
CD, CI, ER, IR, MPH |
| 87 |
2004 |
Anti-nociceptive and sedative effects of sufentanil long acting during and after sevoflurane anaesthesia in dogs. |
--- |
| 88 |
2004 |
Effects of subcutaneous injections of a long acting moxidectin formulation in grazing beef cattle on parasite fecal egg reduction and animal weight gain. |
ADG |
| 89 |
2004 |
Evaluation of the chemoprophylactic efficacy of 10% long acting injectable moxidectin against gastrointestinal nematode infections in calves in Belgium. |
PT, U tyr |
| 90 |
2004 |
Long-acting injectable risperidone. |
--- |
| 91 |
2004 |
Prophylaxis of postoperative nausea and vomiting with oral, long-acting dimenhydrinate in gynecologic outpatient laparoscopy. |
PACU |
| 92 |
2002 |
Efficacy of a new long-acting formulation of ivermectin and other injectable avermectins against induced Psoroptes ovis infestations in cattle. |
LAI |
| 93 |
2001 |
Pharmacokinetics and residues in milk of oxytetracyclines administered parenterally to dairy goats. |
CF, CK, IM, LDH, OTC |
| 94 |
1998 |
Effect of calcium antagonists on sympathetic activity. |
NE, SA |
| 95 |
1997 |
Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. |
NE, SA |
| 96 |
1995 |
Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid. |
HAL, HVA, RBC, RHAL |
| 97 |
1994 |
Effect of propranolol on prevention of first variceal bleed and survival in patients with chronic liver disease. |
--- |
| 98 |
1993 |
Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo controlled study. |
--- |
| 99 |
1992 |
Treatment of Brucella melitensis infection in sheep and goats with oxytetracycline combined with streptomycin. |
IM, OTC, ST |
| 100 |
1991 |
[Slow-release salbutamol in the treatment of nocturnal asthma. Result of a comparative study vs. long-acting theophylline]. |
SRS |
|
A Search Service for Abbreviation / Long Form
